A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

May 8, 2013

Astellas announces a3 (a-cube) selection results on public open innovation site, and start of international invitation for public participation in research

Tokyo, May 8, 2013 – Astellas Pharma Inc. (Astellas; Tokyo: 4503) today announced its selection results based on a3 (a-cube), a website (http://www.astellas.com/jp/a-cube/) launched on May 17,...

Read more about Astellas announces a3 (a-cube) selection results on public open innovation site, and start of international invitation for public participation in research
May 7, 2013

Astellas and Drais Partner To Develop Third Astellas Compound through Tacurion

InterWest Partners, Sutter Hill Ventures and Astellas Venture Management Invest $15 Million into Tacurion to Advance Compound

TOKYO, JAPAN and BRIDGEWATER, N.J., May 7, 2013 – Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) and Drais Pharmaceuticals, Inc. (“Drais”) today announced that they have entered into a...

Read more about Astellas and Drais Partner To Develop Third Astellas Compound through Tacurion
May 2, 2013

AVEO and Astellas Report FDA Oncologic Drug Advisory Committee Votes Tivozanib Application Did Not Demonstrate Favorable Benefit-to-Risk Evaluation in Treatment of Advanced Renal Cell Carcinoma

CAMBRIDGE, Mass. and TOKYO, Japan, May 2, 2013 - AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today reported that the U.S. Food and Drug Administration’s (FDA) Oncologic...

Read more about AVEO and Astellas Report FDA Oncologic Drug Advisory Committee Votes Tivozanib Application Did Not Demonstrate Favorable Benefit-to-Risk Evaluation in Treatment of Advanced Renal Cell Carcinoma
Apr 26, 2013

POSITIVE CHMP OPINION FOR XTANDITM (ENZALUTAMIDE) IN ADVANCED PROSTATE CANCER1

Enzalutamide recommended for approval in the European Union (EU) for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy 1

Chertsey, England and San Francisco, CA; 26 April, 2013: Today, Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. (Nasdaq:...

Read more about POSITIVE CHMP OPINION FOR XTANDITM (ENZALUTAMIDE) IN ADVANCED PROSTATE CANCER1
Apr 25, 2013

Astellas Announces Changes of Representative Directors, Directors and Corporate Auditors

Read more about Astellas Announces Changes of Representative Directors, Directors and Corporate Auditors
Apr 15, 2013

New Hire Reinforces Global Compliance Structure

TOKYO, April 15, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo: 4503) today announced that Songlin Xue, M.D., Ph.D. has been named head of Global Pharmacovigilance (GPV). Dr. Xue will be...

Read more about New Hire Reinforces Global Compliance Structure
Apr 10, 2013

Astellas and Johns Hopkins University researchers identify a novel action of quetiapine in the regulation of cell-cycle related p21/Cdkn1a gene expression in CD-1 mice ～Data Reported in U.S. Scientific Journal, Translational Psychiatry～

TOKYO, April 10, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503) announced today that its collaborative research project with Johns HopkinsUniversity School of Medicine (“JHU”;...

Read more about Astellas and Johns Hopkins University researchers identify a novel action of quetiapine in the regulation of cell-cycle related p21/Cdkn1a gene expression in CD-1 mice ～Data Reported in U.S. Scientific Journal, Translational Psychiatry～
Apr 4, 2013

Astellas and Ambrx Initiate Collaboration for Discovery and Development of Next-Generation Antibody Drug Conjugates for Oncology

TOKYO and SAN DIEGO, April 4, 2013 – Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today entered into a collaboration with Ambrx Inc. (“Ambrx”) for the discovery and development of...

Read more about Astellas and Ambrx Initiate Collaboration for Discovery and Development of Next-Generation Antibody Drug Conjugates for Oncology
Apr 1, 2013

Medivation and Astellas Provide Update on PREVAIL -Companies Announce Phase 3 PREVAIL Interim Analysis Expected to Occur in 2013-

San Francisco, CA and Tokyo, Japan – April 1, 2013 – Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that the companies have established an updated interim...

Read more about Medivation and Astellas Provide Update on PREVAIL -Companies Announce Phase 3 PREVAIL Interim Analysis Expected to Occur in 2013-
Mar 25, 2013

Approval in Japan for Treating Functional Dyspepsia with Acofide®

Tokyo, March 25, 2013 - Zeria Pharmaceutical Co., Ltd. (Tokyo: 4559; “Zeria”) and Astellas Pharma Inc. (Tokyo: 4503; “Astellas”) announced today that as of March 25, Zeria has obtained the...

Read more about Approval in Japan for Treating Functional Dyspepsia with Acofide®

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts